MSN 620 BOARD EVALUATION 2026
GUARANTEED PASS ANSWERS GRADED A+
● Anaplastic lymphoma kinase translocation (ALK). Answer: Identified
in approximately 4% of adenocarcinomas in the US and seen in
nonsmokers and younger patients.
● Common sites of metastasis. Answer: Liver, bone, adrenal glands, and
brain
● Symptoms associated with metastasis. Answer: Weight loss more than
10 lbs, focal skeletal pain, HA, extremity weakness
● Superior vena cava syndrome. Answer: Common cause due to lung
cancer resulting in facial edema, plethora, dilated neck veins, and a
prominent venous pattern on the chest
● Lung cancer is a hypercoagulable state. Answer: Patients can present
with DVT
● CBC in lung cancer. Answer: Anemia, leukocytosis, and/or
thrombocytosis
, ● CMP in lung cancer. Answer: SIADH, hypercalcemia, possible
abnormal liver function test, elevation in alkaline phosphate
● Stage 1 lung cancer. Answer: Treated with lobectomy or
pneumonectomy with mediastinal lymph node sampling
● Stage 2 lung cancer. Answer: Along with surgery, adjuvant
chemotherapy is recommended
● Non surgical candidates stage 1 & 2. Answer: Stereotactic body
radiation therapy (SBRT), stage 2 received combination treatment with
chemotherapy
● Stage 3 lung cancer. Answer: 5-year overall survival 13-36%, stage 3A
all treatment option at various steps, stage 3B is unresectable with
primary treatment being chemoradiation therapy
● acute bronchitis. Answer: an inflammation of the lower respiratory
tract that is usually due to viral infection
● Stage 4 lung cancer. Answer: Considered not curable, palliative, 1-
year survival 40%, 2-year survival 20%, 10-12 months survival for
metastatic NSCLC
GUARANTEED PASS ANSWERS GRADED A+
● Anaplastic lymphoma kinase translocation (ALK). Answer: Identified
in approximately 4% of adenocarcinomas in the US and seen in
nonsmokers and younger patients.
● Common sites of metastasis. Answer: Liver, bone, adrenal glands, and
brain
● Symptoms associated with metastasis. Answer: Weight loss more than
10 lbs, focal skeletal pain, HA, extremity weakness
● Superior vena cava syndrome. Answer: Common cause due to lung
cancer resulting in facial edema, plethora, dilated neck veins, and a
prominent venous pattern on the chest
● Lung cancer is a hypercoagulable state. Answer: Patients can present
with DVT
● CBC in lung cancer. Answer: Anemia, leukocytosis, and/or
thrombocytosis
, ● CMP in lung cancer. Answer: SIADH, hypercalcemia, possible
abnormal liver function test, elevation in alkaline phosphate
● Stage 1 lung cancer. Answer: Treated with lobectomy or
pneumonectomy with mediastinal lymph node sampling
● Stage 2 lung cancer. Answer: Along with surgery, adjuvant
chemotherapy is recommended
● Non surgical candidates stage 1 & 2. Answer: Stereotactic body
radiation therapy (SBRT), stage 2 received combination treatment with
chemotherapy
● Stage 3 lung cancer. Answer: 5-year overall survival 13-36%, stage 3A
all treatment option at various steps, stage 3B is unresectable with
primary treatment being chemoradiation therapy
● acute bronchitis. Answer: an inflammation of the lower respiratory
tract that is usually due to viral infection
● Stage 4 lung cancer. Answer: Considered not curable, palliative, 1-
year survival 40%, 2-year survival 20%, 10-12 months survival for
metastatic NSCLC
